8-K: NRC Health Reports Q2 2025 Net Loss Amid Executive Compensation Costs, Despite Sequential TRCV Growth

NRC Health announced a net loss for the second quarter of 2025, primarily due to significant non-recurring executive compensation, even as it achieved its third consecutive quarter of sequential Total Recurring Contract Value (TRCV) growth.

Summary

• NRC Health reported a net loss of $106,000 for the second quarter ended June 30, 2025, a significant decline from a net income of $6.175 million in the same period last year.
• Basic earnings per share (EPS) for Q2 2025 was $(0.01), down from $0.26 in Q2 2024.
• Revenue for Q2 2025 was $34.038 million, a decrease from $35.021 million in Q2 2024.
• Total Recurring Contract Value (TRCV) grew 2% sequentially, marking the third consecutive quarter of TRCV growth and the highest sequential growth rate since Q1 2021.
• The net margin for Q2 2025 was 0%, primarily due to $6.640 million in non-recurring cash bonuses and equity grants for executive leaders.
• Excluding these one-time items, adjusted EBITDA margin was 30% in Q2 2025, remaining relatively stable over the past year.
• The company repurchased 381,736 shares at a weighted average price of $14.96 per share during the second quarter.
• A quarterly cash dividend of $0.12 per share was declared, payable on October 10, 2025, to shareholders of record as of September 26, 2025.
• NRC Health has returned a total of $16.1 million to shareholders through dividends and stock repurchases during 2025.
• The company will reinstate its quarterly earnings call on July 29, 2025, at 10 a.m. ET.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While operational metrics like TRCV growth and adjusted EBITDA margin show underlying strength and positive momentum, the significant net loss and negative EPS due to one-time executive compensation costs overshadow these positives. The company is returning capital to shareholders, which is positive, but the GAAP profitability decline is a major concern.

Positives

• Achieved third consecutive quarter of sequential Total Recurring Contract Value (TRCV) growth, increasing 2%.
• Recorded the highest sequential TRCV growth rate since the first quarter of 2021.
• Improved new logo sales, cross-sells, and customer retention, attributed to a stronger sales team, resonant product portfolio, and strong customer service.
• Adjusted EBITDA margin remained stable at 30% in Q2 2025, indicating underlying operational efficiency despite one-time costs.
• Returned $16.1 million to shareholders in 2025 through dividends and stock repurchases.
• Reinstated quarterly earnings calls, signaling increased transparency and direct communication with investors.

Negatives

• Reported a net loss of $106,000 in Q2 2025, a significant decline from a net income of $6.175 million in Q2 2024.
• Basic earnings per share (EPS) fell to $(0.01) in Q2 2025 from $0.26 in Q2 2024.
• Revenue decreased to $34.038 million in Q2 2025 from $35.021 million in Q2 2024.
• Operating income significantly declined to $1.588 million in Q2 2025 from $8.865 million in Q2 2024.
• Net margin was 0% for Q2 2025, primarily due to $6.640 million in non-recurring executive compensation arrangements.

Risks

• Forward-looking statements, including those related to future dividends, share repurchases, and revenue, are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified.
• Risks and uncertainties that could cause future events and actual results to differ materially are detailed in the Risk Factors section of the company's Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings.

Future Outlook

Statements related to future dividends, share repurchases, and revenue are considered forward-looking. The company has declared a future dividend and continues its share repurchase program, but no specific quantitative guidance for future revenue or profitability is provided beyond these general intentions.

Management Comments

• "Were encouraged by our second-quarter results, which demonstrate continued momentum across key areas of our business."
• "In my early weeks as CEO, Ive been energized by feedback from both current and prospective customers, particularly their enthusiasm for our product portfolio and appreciation for the service mindset of our associates."
• "To provide additional context on the quarter, were reinstating our quarterly earnings call, which I hope investors will join tomorrow, July 29, at 10 a.m. ET."

Industry Context

NRC Health operates in the healthcare technology and patient experience sector, which is increasingly focused on humanizing healthcare and understanding individual consumer preferences. The company's reported TRCV growth and stable adjusted EBITDA margin suggest its product portfolio and customer service resonate in a market that values strong patient outcomes and efficient healthcare systems. The emphasis on 'Human Understanding' aligns with broader industry trends towards patient-centric care and data-driven insights.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess NRC Health's performance against direct competitors or broader industry standards. However, the 30% Adjusted EBITDA margin suggests a healthy operational efficiency, which would generally be considered competitive within the software and healthcare IT services sector, though specific comparisons would require detailed competitor analysis.
• The sequential TRCV growth indicates positive sales momentum, which is a key performance indicator for SaaS-like businesses in the healthcare technology space, suggesting the company is gaining or retaining market share.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Experienced a net loss and negative EPS for the quarter, but benefited from a declared dividend and ongoing share repurchases, with $16.1 million returned year-to-date. New executive compensation aims for long-term alignment.
• **Customers:** Positive feedback on the product portfolio and service mindset, indicating strong customer satisfaction and retention.
• **Employees (Associates):** Praised for their service mindset, contributing to customer appreciation.

Next Steps

• Host an earnings call on July 29, 2025, at 10 a.m. ET, to provide additional detail on the quarter.
• Pay the declared quarterly cash dividend of $0.12 per share on October 10, 2025.

Key Dates

Recommendation

The stock is a 'hold' because while the company reported a net loss and negative EPS due to significant one-time executive compensation, underlying operational metrics like sequential TRCV growth and stable adjusted EBITDA margin show positive momentum and resilience. The new CEO's focus on customer feedback and the reinstatement of earnings calls suggest a commitment to transparency and strategic improvement. However, the substantial impact of the one-time costs on GAAP profitability warrants caution. Investors should monitor future quarters to see if the operational improvements translate into sustained GAAP net income growth and if these one-time costs are truly non-recurring, before considering a 'buy' or 'sell' position.

Keywords

Healthcare technology, Patient experience, Healthcare analytics, Customer retention, TRCV, EBITDA, Share repurchase, Dividend, SEC filing, Earnings report